These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 25439370)
21. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. Kim JH; Xi S; Ference EH; Ge M; Liu MM; Wrobel BB Int Forum Allergy Rhinol; 2020 Aug; 10(8):996-1000. PubMed ID: 32407593 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Schwartz LB Immunol Allergy Clin North Am; 2006 Aug; 26(3):451-63. PubMed ID: 16931288 [TBL] [Abstract][Full Text] [Related]
23. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders. Zaghmout T; Maclachlan L; Bedi N; Gülen T J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692 [TBL] [Abstract][Full Text] [Related]
24. Using the Right Criteria for MCAS. Gulen T Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020 [TBL] [Abstract][Full Text] [Related]
33. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. Schwartz LB; Metcalfe DD; Miller JS; Earl H; Sullivan T N Engl J Med; 1987 Jun; 316(26):1622-6. PubMed ID: 3295549 [TBL] [Abstract][Full Text] [Related]
34. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. Hamilton MJ Immunol Allergy Clin North Am; 2018 Aug; 38(3):469-481. PubMed ID: 30007464 [TBL] [Abstract][Full Text] [Related]
35. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Potier A; Lavigne C; Chappard D; Verret JL; Chevailler A; Nicolie B; Drouet M Clin Exp Allergy; 2009 May; 39(5):717-25. PubMed ID: 19302252 [TBL] [Abstract][Full Text] [Related]
36. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Valent P; Akin C; Arock M; Brockow K; Butterfield JH; Carter MC; Castells M; Escribano L; Hartmann K; Lieberman P; Nedoszytko B; Orfao A; Schwartz LB; Sotlar K; Sperr WR; Triggiani M; Valenta R; Horny HP; Metcalfe DD Int Arch Allergy Immunol; 2012; 157(3):215-25. PubMed ID: 22041891 [TBL] [Abstract][Full Text] [Related]
37. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675 [TBL] [Abstract][Full Text] [Related]
38. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome. Butterfield J; Weiler CR J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966 [TBL] [Abstract][Full Text] [Related]
39. Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis. Heide R; van Doorn K; Mulder PG; van Toorenenbergen AW; Beishuizen A; de Groot H; Tank B; Oranje AP Clin Exp Dermatol; 2009 Jun; 34(4):462-8. PubMed ID: 19077102 [TBL] [Abstract][Full Text] [Related]